Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.55 |
| ▸ | KDR | P35968 | 14/20 | 0.55 |
| ▸ | RET | P07949 | 2/20 | 0.52 |
| ▸ | KIF5B | P33176 | 1/20 | 0.52 |
| ▸ | FLT4 | P35916 | 3/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.51 |
| ▸ | FLT1 | P17948 | 2/20 | 0.51 |
| ▸ | CSF1R | P07333 | 2/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | TEK | Q02763 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30394371 | 0.90 | AURKA (0.54) | EGFRKDRRETKIF5BFLT4 | |
| SCHEMBL26101303 | 0.90 | AURKA (0.54) | EGFRKDRRETKIF5BFLT4 | |
| SCHEMBL30394478 | 0.88 | PDGFRB (0.54) | EGFRKDRAURKAPDGFRBKIT | |
| SCHEMBL26099266 | 0.82 | KDR (0.59) | EGFRKDRRETKIF5BFLT4 | |
| SCHEMBL30891764 | 0.82 | KDR (0.59) | EGFRKDRRETKIF5BFLT4 | |
| SCHEMBL26101911 | 0.81 | CSF1R (0.53) | EGFRKDRRETKIF5BFLT4 | |
| SCHEMBL26101960 | 0.80 | KDR (0.54) | EGFRKDRRETKIF5BFLT4 | |
| SCHEMBL31137829 | 0.80 | KDR (0.57) | EGFRKDRRETKIF5BFLT4 | |
| SCHEMBL26098307 | 0.80 | KDR (0.57) | EGFRKDRRETKIF5BFLT4 | |
| SCHEMBL26101506 | 0.79 | KDR (0.53) | EGFRKDRRETKIF5BFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138959-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC (KR) | 2026-05-21 | — | — | US | claimed |
| EP-4424675-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | Voronoi Inc. (KR) | 2024-09-04 | — | — | EP | claimed |
| CN-118201909-A | Quinazoline derivative compound and use thereof | 株式会社沃若诺伊 | 2024-06-14 | — | — | CN | claimed |
| WO-2023075529-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | 보로노이바이오 주식회사 | 2023-05-04 | — | — | WO | claimed |
| EP-4424675-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | Voronoi Inc. (KR) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023075529-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | 보로노이바이오 주식회사 | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138959-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | PDGFRA, KIT, PDGFRB | EGFR 79/4885KDR 5/4885RET 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.